Nuformix plc (LSE:NFX), a small London-listed pharmaceutical development company, has reported fresh preclinical data for NXP002, its inhaled candidate for fibrotic lung disease. In an update dated 19 August 2026, the company described what its latest animal studies showed. This article looks at how the programme has advanced and the finances supporting it.
A drug-repurposing specialist
Nuformix (LSE:NFX) describes itself as a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology through drug repurposing, developing new formulations of existing compounds with improved properties. Its shares trade on the London Stock Exchange Main Market under the code NFX. The company's lead programme is NXP002, which it is developing as a nebulised inhaled treatment for idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis and other progressive fibrosing interstitial lung diseases. The August announcement does not name the underlying molecule, so that detail is not stated here.
The approach delivers a drug directly into the lungs, where fibrosis occurs. Whether this actually improves outcomes remains untested in humans.
What the August update reported
According to the 19 August RNS, NXP002 was successfully nebulised across a broad range of doses and produced substantial, dose-related exposure in the lungs. The company said lung concentrations fell within ranges it considers therapeutically relevant, based on earlier work using precision-cut slices of human IPF lung tissue. It also reported reduced expression of alpha-smooth muscle actin, which it presented as evidence of engagement with the fibrosis pathway.
Executive director Dr Dan Gooding said: "We have demonstrated that inhaled administration can achieve lung concentrations within the range expected to be therapeutically relevant based on our previous studies in human IPF lung tissue, alongside meaningful surrogate evidence of target/pathway engagement in vivo with direct relevance to the lung fibrosis phenotype." The company said non-GLP dose-range-finding studies were progressing and that it planned to present at the European Respiratory Society Congress in Barcelona from 5 to 9 September 2026.
Earlier, in March 2026, NXP002 received Orphan Drug Designation from the US Food and Drug Administration for IPF, following a prior designation in Europe. According to the half-year report, such status can bring development incentives including tax credits and potential seven years of US Marketing exclusivity if a product is approved.
Finances and governance
For the six months to 31 March 2026, Nuformix reported a loss of £346,577, compared with £376,668 a year earlier, and a loss per share of 0.02p. Cash at the period end was £930,283 and net Assets were £1,636,439. The company raised £228,081 through an open offer in November 2025 and £1,000,000 through a placing in March 2026, both at 0.2p per share. The directors said they had adequate resources to continue as a going concern, based on Cash Flow forecasts running to December 2027.
On 25 August 2026, the company announced that Tim Metcalfe, a corporate finance professional with more than 30 years' experience, would become non-executive chairman from 1 September, succeeding Julian Gilbert, who remains as a consultant.
Risks to consider
NXP002 remains at a preclinical stage, and results in animal models and tissue samples frequently Fail to translate into clinical benefit. Further toxicology work, regulatory filings and human trials will require funding well beyond the company's current cash, and further Equity raises may mean continuing dilution. The half-year report states that the strategy centres on securing licensing partners, and no Partnership has yet been announced. The IPF market also includes established therapies against which any new treatment would be judged.
Conclusion
Nuformix advanced NXP002 by showing, in preclinical studies, that the nebulised drug reached the lungs at concentrations it considers relevant and engaged fibrosis-related biology. That builds on US orphan status, but the programme's value still depends on clinical proof and partnering.






Please wait processing your request...